MA27293A1 - Synthese d'analogues de la cyclosporine - Google Patents

Synthese d'analogues de la cyclosporine

Info

Publication number
MA27293A1
MA27293A1 MA27597A MA27597A MA27293A1 MA 27293 A1 MA27293 A1 MA 27293A1 MA 27597 A MA27597 A MA 27597A MA 27597 A MA27597 A MA 27597A MA 27293 A1 MA27293 A1 MA 27293A1
Authority
MA
Morocco
Prior art keywords
ciclosporin
isomers
analogs
weight
isatx247
Prior art date
Application number
MA27597A
Other languages
English (en)
Inventor
Selvaraj Naicker
Randall W Yatscoff
Robert T Foster
Mark Abel
Seetharaman Jayaraman
Hans-Jurgen Mair
Jean-Michel Adam
Bruno Lohri
Original Assignee
Isotechnika Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isotechnika Inc filed Critical Isotechnika Inc
Publication of MA27293A1 publication Critical patent/MA27293A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Abstract

L'invention concerne des mélanges isomères d'analogues de la ciclosporine qui sont structurellement semblables à la ciclosporine A. Les mélanges ont une efficacité améliorée et une toxicité réduite par rapport aux isomères individuels et par rapport aux ciclosporines et dérivés de la ciclosporine naturels et présentement connus. Les modes de réalisation de la présente invention concernent des isomères cis et trans d'analogues de la ciclosporine A cités ISATX247, et des dérivés de ceux-ci. Les isomères d'ISATX247 et les dérivés alkylés, arylés, et deutérés sont synthétisés par des processus stéréosélectifs oé les conditions particulières d'une réaction déterminent le degrée de stéréosélectivité. Les processus stéréosélectifs peuvent utiliser une réaction de Wittig, ou un réactif organométallique comprenant des éléments inorganiques tels que les bore, silicium, titanium et lithium. Le rapport des isomères dans un mélange peut varier de 10 à 90 pour cent environ en poids d'isomère (E) pour environ 90 à 10 pour cent en poids d'isomère (Z), basé sur le poids total du mélange.
MA27597A 2001-10-19 2004-03-26 Synthese d'analogues de la cyclosporine MA27293A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34620101P 2001-10-19 2001-10-19
US37059602P 2002-04-05 2002-04-05

Publications (1)

Publication Number Publication Date
MA27293A1 true MA27293A1 (fr) 2005-05-02

Family

ID=26994746

Family Applications (1)

Application Number Title Priority Date Filing Date
MA27597A MA27293A1 (fr) 2001-10-19 2004-03-26 Synthese d'analogues de la cyclosporine

Country Status (28)

Country Link
US (13) US6998385B2 (fr)
EP (2) EP1714977B1 (fr)
JP (3) JP4261355B2 (fr)
KR (2) KR100982466B1 (fr)
CN (1) CN100334106C (fr)
AT (2) ATE332917T1 (fr)
AU (2) AU2002331509B2 (fr)
BR (1) BRPI0213658A8 (fr)
CA (1) CA2461740C (fr)
CO (1) CO5580836A2 (fr)
CY (1) CY1105111T1 (fr)
DE (2) DE60231570D1 (fr)
DK (2) DK1714977T3 (fr)
ES (2) ES2326040T3 (fr)
HK (1) HK1062568A1 (fr)
HR (2) HRP20040355B1 (fr)
IL (3) IL160763A0 (fr)
MA (1) MA27293A1 (fr)
MX (1) MXPA04003625A (fr)
NO (1) NO332459B1 (fr)
NZ (1) NZ531944A (fr)
PL (2) PL210841B1 (fr)
PT (2) PT1714977E (fr)
RU (1) RU2321593C9 (fr)
SI (1) SI1436321T1 (fr)
TN (1) TNSN04068A1 (fr)
WO (1) WO2003033526A2 (fr)
ZA (1) ZA200402269B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
PL210697B1 (pl) * 2001-10-19 2012-02-29 Isotechnika Inc Kompozycja zawierająca mieszaninę izomerów analogu cyklosporyny i zastosowanie tej mieszaniny
BRPI0213658A8 (pt) 2001-10-19 2016-12-06 F Hoffmann La Roche Ltd Método para preparar uma mistura isomérica predeterminada ou não dos análogos de ciclosporina a modificados no resíduo de 1-aminoácido, métodopara produzir uma mistura enriquecida com e-isômero ou com z-isômero de análogos de ciclosporina a modificados no resíduo de 1-aminoácido, mistura de (e) e (z)-isômeros, composição, método para a síntese estereoseletiva do z-isômero de isatx247, método para a preparação de aldeído do ciclosporina a
AU2004222306A1 (en) * 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
US20040266669A1 (en) * 2003-06-20 2004-12-30 Wu Frank X. H. Cyclosporin derivatives for the treatment of immune disorders
CA2575280C (fr) * 2004-07-29 2012-08-14 Amr Technology, Inc. Nouveaux procedes de synthese stereoselective d'un compose isa<sb>tx</sb>247 trans
US7378391B2 (en) * 2004-09-29 2008-05-27 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
US7511013B2 (en) * 2004-09-29 2009-03-31 Amr Technology, Inc. Cyclosporin analogues and their pharmaceutical uses
JP2008515886A (ja) * 2004-10-06 2008-05-15 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキンおよびそれらの医用薬剤としての有用性
CN101120012A (zh) * 2004-12-17 2008-02-06 伊素制药公司 环孢菌素类似物的代谢物
WO2007028030A2 (fr) * 2005-09-02 2007-03-08 Picobella, Llc Arn regulateurs oncogenes pour le diagnostic et la therapie
US7459280B2 (en) * 2006-02-27 2008-12-02 Picobella, Llc Methods for diagnosing and treating kidney cancer
US20070232532A1 (en) * 2006-03-28 2007-10-04 Amr Technology, Inc. Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US20080267977A1 (en) * 2007-04-26 2008-10-30 Friedrich-Alexander University Of Erlangen-Nuremberg Combined immunological agent and sensitizing agent for the treatment of cancer
CA3014633C (fr) * 2007-10-08 2022-05-17 Aurinia Pharmaceuticals Inc. Compositions ophtalmiques comprenant des inhibiteurs de la calcineurine ou des inhibiteurs de mtor
EP2151450A1 (fr) * 2008-07-29 2010-02-10 Sandoz AG Procédé de préparation d'oligopeptides cycliques microbiologiques
US20130190223A1 (en) * 2008-07-30 2013-07-25 Isotechnika Pharma Inc. Nonimmunosuppressive cyclosporine analogue molecules
DE102008060549A1 (de) 2008-12-04 2010-06-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
CA2751210C (fr) 2009-01-30 2015-04-21 Enanta Pharmaceuticals, Inc. Analogues de la cyclosporine pour prevenir ou traiter une infection par l'hepatite c
US8481483B2 (en) 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
CA2764635C (fr) 2009-06-09 2018-05-22 Lux Biosciences, Inc. Systemes d'administration de medicament topique pour une utilisation ophtalmique
US8685917B2 (en) 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8367053B2 (en) 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
GB0912584D0 (en) * 2009-07-20 2009-08-26 Ucl Business Plc Cyclosporin conjugates
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
NZ611620A (en) 2010-12-15 2016-02-26 Ciclofilin Pharmaceuticals Corp Cyclosporine analogue molecules modified at amino acid 1 and 3
WO2012103520A1 (fr) * 2011-01-28 2012-08-02 Board Of Regents Of The University Of Nebraska Procédés et compositions pour moduler la cyclophiline d
US10429712B2 (en) 2012-04-20 2019-10-01 View, Inc. Angled bus bar
WO2012145426A1 (fr) 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Procédés pour traiter un cancer utilisant la cyclosporine et des dérivés de cyclosporine
JP6401609B2 (ja) 2011-04-29 2018-10-10 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 抗体反応を低下させる寛容原性合成ナノキャリア
AR090964A1 (es) * 2012-05-09 2014-12-17 Novartis Ag Proceso para la elaboracion de undecapeptidos ciclicos
CN104487449A (zh) 2012-06-01 2015-04-01 阿勒根公司 环孢菌素a类似物
EP2705856A1 (fr) 2012-09-07 2014-03-12 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. Composés pour le traitement de troubles neurodégénératifs
WO2014085623A1 (fr) 2012-11-28 2014-06-05 Enanta Pharmaceuticals, Inc. Nouveaux analogues de [n-me-4-hydroxyleucine]-9-cyclosporine
KR20150139899A (ko) 2013-04-01 2015-12-14 알러간, 인코포레이티드 지속적인 안구내 방출을 위한 마이크로스피어 약물 전달 시스템
CN110841066A (zh) 2013-05-03 2020-02-28 西莱克塔生物科技公司 用于降低的或增强的药效学作用的致耐受性合成纳米载体和治疗性大分子
TWI685706B (zh) 2013-06-18 2020-02-21 唯景公司 非矩形之電致變色裝置
KR20160045136A (ko) 2013-08-26 2016-04-26 이난타 파마슈티칼스, 인코포레이티드 C형 간염을 예방 또는 치료하기 위한 사이클로스포린 유사체
BR112017001311A2 (pt) 2014-09-07 2017-11-14 Selecta Biosciences Inc métodos e composições para atenuar as respostas imunes do vetor de transferência anti-viral de salto de éxon
WO2016073480A1 (fr) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Analogues de cyclosporine pour prévenir ou traiter une infection par l'hépatite c
US10745413B2 (en) * 2014-12-17 2020-08-18 Verrica Pharmaceuticals, Inc. Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
CN106554392B (zh) * 2016-11-21 2019-10-25 石家庄中天生物技术有限责任公司 一种高纯度环孢菌素衍生物stg-175的制备方法
BR112019018748A2 (pt) 2017-03-11 2020-04-07 Selecta Biosciences Inc métodos e composições relacionados ao tratamento combinado com anti-inflamatórios e nanocarreadores sintéticos compreendendo um imunossupressor
US10286036B2 (en) 2017-05-12 2019-05-14 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
US11584779B2 (en) 2018-10-19 2023-02-21 Teva Pharmaceuticals International Gmbh Solid state forms of voclosporin
EP4201952A1 (fr) 2021-12-21 2023-06-28 Curia Spain, S.A.U. Procédé de synthèse contrôlée de voclosporine

Family Cites Families (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US525590A (en) * 1894-09-04 canda
CH614931A5 (fr) * 1975-11-04 1979-12-28 Sandoz Ag
US4210581A (en) * 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
US4117118A (en) 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
DK25877A (da) 1977-01-21 1978-08-15 Nordisk Insulinlab Fremgangsmaade til udvinding af renset albumin fra blodplasma
US4256108A (en) * 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4160452A (en) * 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
CH628022A5 (en) 1977-05-10 1982-02-15 Sandoz Ag Process for the preparation of an antibiotic derivative
CH630061A5 (en) 1977-05-10 1982-05-28 Sandoz Ag Process for the preparation of an antibiotic derivative
DE2819094A1 (de) * 1977-05-10 1978-11-23 Sandoz Ag Cyclosporin-derivate, ihre verwendung und herstellung
CH630062A5 (en) 1977-05-23 1982-05-28 Sandoz Ag Process for the preparation of an antibiotic derivative
SE448386B (sv) 1978-10-18 1987-02-16 Sandoz Ag Nya cyklosporinderivat, forfarande for framstellning av dem samt farmaceutisk komposition innehallande dem
US4201771A (en) 1979-03-12 1980-05-06 Merck & Co., Inc. Antibiotic A43F
US4396542A (en) * 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
ATE43335T1 (de) 1980-02-14 1989-06-15 Sandoz Ag Peptide die einen (1s,2r,3r)- oder (1r,2s,3s)-1nitrilo-1-carbonyl-3-methyl-2-oxyheptan oder hept-5-en-rest enthalten brauchbar in totaler synsthese von cyclosporinen, und verfahren zu ihrer herstellung.
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
FR2487198A1 (fr) 1980-07-28 1982-01-29 Berri Balzac Sa Nouvelle substance immuno-suppressive, son procede d'isolement et son application en therapeutique
US4304641A (en) 1980-11-24 1981-12-08 International Business Machines Corporation Rotary electroplating cell with controlled current distribution
DE3260468D1 (en) 1981-01-09 1984-09-06 Sandoz Ag Novel cyclosporins
CH667274A5 (de) 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
NZ212051A (en) 1984-05-18 1988-10-28 Univ Australian Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
US5639724A (en) 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
GB8422253D0 (en) 1984-09-04 1984-10-10 Sandoz Ltd Organic compounds
US5169773A (en) 1984-10-04 1992-12-08 Sandoz Ltd. Monoclonal antibodies to cyclosporins
EP0198026B1 (fr) 1984-10-04 1993-08-04 Sandoz Ag Anticorps monoclonaux contre les cyclosporines
EP0194972B1 (fr) * 1985-03-11 1992-07-29 Sandoz Ag Cyclosporines
US5047512A (en) 1985-05-03 1991-09-10 Handschumacher Robert E Immobilized cyclophilin and methods of using such
DE3531597A1 (de) 1985-09-04 1987-03-05 Bioferon Biochem Substanz Verwendung von interferon-gamma (ifn-gamma) enthaltenden praeparationen zur behandlung psoriatischer erkrankungen
US4765980A (en) 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
CH670644A5 (fr) * 1986-12-18 1989-06-30 Lonza Ag
US4764503A (en) 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
US4963683A (en) * 1986-12-18 1990-10-16 Sri International Process for preparing polyoxa tetracyclic compounds
NL194638C (nl) 1986-12-19 2002-10-04 Novartis Ag Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
US5084441A (en) 1987-03-04 1992-01-28 Shaw Jack M Acetylated low density lipoproteins: a delivery system to phagocytic cells for stimulating immunologic response and host resistance
US5239057A (en) * 1987-03-27 1993-08-24 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
EP0283801A3 (fr) 1987-03-27 1990-05-30 Abbott Laboratories Essais de polarisation par fluorescence pour cyclosporine A et les métabolites et immunogènes et anticorps apparentés
US5427960A (en) 1987-03-27 1995-06-27 Abbott Laboratories Fluorescence polarization assay for cyclosporin A and metabolites and related immunogens and antibodies
US4885276A (en) 1987-06-03 1989-12-05 Merck & Co., Inc. Cyclosporin analogs with modified "C-9 amino acids"
US4798823A (en) 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"
JP2577049B2 (ja) 1987-06-04 1997-01-29 三共株式会社 シクロスポリン製剤
ATE95193T1 (de) * 1987-06-17 1993-10-15 Sandoz Ag Cyclosporine und deren benutzung als arzneimittel.
DE3851268T2 (de) 1987-06-19 1995-01-26 Sandoz Ag Zyklische Peptolide.
DE3888357T2 (de) 1987-06-22 1994-09-15 Merck & Co Inc Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen.
GB2206119B (en) 1987-06-22 1990-10-31 Merck & Co Inc A new cyclosporin derivative with modified "8-amino acid"
GB8717300D0 (en) 1987-07-22 1987-08-26 Nat Res Dev Cyclosporins
GB8717299D0 (en) 1987-07-22 1987-08-26 Nat Res Dev Peptides
US5227467A (en) 1987-08-03 1993-07-13 Merck & Co., Inc. Immunosuppressive fluorinated cyclosporin analogs
GB2207678A (en) 1987-08-03 1989-02-08 Merck & Co Inc Novel immunosuppressive fluorinated cyclosporin analogs
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
EP0391909B1 (fr) 1987-09-03 1994-08-17 The University Of Georgia Research Foundation, Inc. Composition de cyclosporine oculaire
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
US5089390A (en) 1987-09-04 1992-02-18 Syntex (U.S.A.) Inc. 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
US4868155A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US4866036A (en) 1987-10-05 1989-09-12 Merck & Co., Inc. Dipeptidyl 5-0,6-0-acyl-2-amino-2-deoxy-D-glucofuranose compositions and methods of use in aids-immunocompromised human hosts
US4868157A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 2-amino-1,2-dideoxy-D-glucose derivatives as host resistance enhancers in AIDS-immunocompromised hosts and methods of use
US4914188A (en) 1987-11-16 1990-04-03 Merck & Co., Inc. Novel 6-position cyclosporin analogs as non-immunosuppressive antagonists of cyclosporin binding to cyclophilin
US5236899A (en) 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
GB8729153D0 (en) 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
US5693760A (en) 1988-04-14 1997-12-02 Incyte Pharmaceuticals, Inc. Method of causing selective immunosuppression using HL-60 related lectins
WO1989010351A1 (fr) 1988-04-21 1989-11-02 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis Nouveaux analogues de vitamine d
JPH0774799B2 (ja) 1988-04-28 1995-08-09 積水化学工業株式会社 血中成分の測定法
EP0430968B1 (fr) 1988-05-02 1996-11-20 PHANOS TECHNOLOGIES, Inc. Composes, compositions et procede de liaison de substances de bio-affection sur des membranes superficielles de bio-particules
US5013719A (en) 1988-05-13 1991-05-07 Merrell Dow Pharmaceuticals Inc. Method of effecting immunosuppression
DE3927804A1 (de) 1988-08-24 1990-03-01 Boehringer Ingelheim Kg Verwendung von paf-antagonisten zur behandlung von autoimmunerkrankungen
EP0436020A4 (en) 1988-09-14 1992-03-25 Yoshitomi Pharmaceutical Industries, Ltd. Immunosuppressant
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
JPH02124100A (ja) 1988-11-02 1990-05-11 Tonen Corp プロリルイソメラーゼの使用方法
US5632991A (en) 1988-11-14 1997-05-27 Brigham & Women's Hospital Antibodies specific for E-selectin and the uses thereof
US5698448A (en) 1988-12-02 1997-12-16 Soldin; Steven J. Immunosuppressive drug binding proteins and use
AU630901B2 (en) 1988-12-02 1992-11-12 Children's Research Institute Cyclosporine binding protein and use in an assay for biologically-active cyclosporine
AU4958590A (en) 1988-12-05 1990-07-10 Trustees Of Columbia University In The City Of New York, The Novel derivatives of cyclosporine a, antibodies directed thereto and uses thereof
AU4597489A (en) 1988-12-09 1990-06-14 G.D. Searle & Co. Method for imparting immunosuppression
US5100889A (en) 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
US5153327A (en) 1988-12-23 1992-10-06 E. R. Squibb & Sons, Inc. 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
GB2227244A (en) 1989-01-19 1990-07-25 Merck & Co Inc Immunosuppressive fluorinated cyclosporin analogs
US4996193A (en) 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5540931A (en) 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5401731A (en) 1989-06-29 1995-03-28 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Productionsaktieselskab) Vitamin D analogues
US5068247A (en) 1989-07-07 1991-11-26 Yoshitomi Pharmaceutical Industries, Ltd. 2-aminopentanoic acid compounds and their use as immunosuppressants
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
US5665543A (en) * 1989-07-18 1997-09-09 Oncogene Science, Inc. Method of discovering chemicals capable of functioning as gene expression modulators
GB8916901D0 (en) 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
US5284826A (en) 1989-07-24 1994-02-08 Sandoz Ltd. 0-hydroxyethyl and acyloxyethyl derivatives of [ser]8 cyclosporins
US5356633A (en) 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
CS277472B6 (cs) 1989-11-16 1993-03-17 Alexandr Rndr Csc Jegorov Způsob výroby derivátů cyklosporinu A
CS277471B6 (cs) 1989-11-16 1993-03-17 Alexandr Rndr Csc Jegorov Deriváty cyklosporinu A
US5591623A (en) 1990-08-14 1997-01-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5514788A (en) 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5129884A (en) * 1990-01-16 1992-07-14 Dysarz Edward D Trap in barrel one handed retracted intervenous catheter device
US5171812A (en) 1990-01-19 1992-12-15 Nova Pharmaceutical Corporation Polyanhydrides of oligomerized unsaturated aliphatic acids
US5270419A (en) 1990-01-19 1993-12-14 Nova Pharmaceutical Corporation Polyanhydrides of oligomerized unsaturated aliphatic acids
US5122511A (en) 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US5214130A (en) 1990-02-27 1993-05-25 Merck & Co., Inc. Synthesis of novel immunosuppressive cyclosporin analogs with modified amino acids at position-8
DE4013910A1 (de) 1990-04-26 1991-10-31 Schering Ag Kombinationspraeparat zur immunsuppressiven therapie
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
DK0473961T3 (da) * 1990-08-15 1996-07-01 Abbott Lab Immunoassay-reagenser og fremgangsmåde til bestemmelse af cyklosporin
GB9017890D0 (en) 1990-08-15 1990-09-26 Leo Pharm Prod Ltd Chemical compounds i
WO1992004055A1 (fr) 1990-09-06 1992-03-19 The Australian National University Composition immunosuppressive
SK278808B6 (sk) * 1990-11-02 1998-03-04 Novartis Ag Cyklosporíny, ich použitie pri príprave liečiva na
CA2055813A1 (fr) 1990-11-20 1992-05-21 Dariush Davalian Dosage immunologique de la cyclosporine
EP0507968B1 (fr) 1991-04-06 1995-09-06 Arzneimittelwerk Dresden Gmbh Procédé de production par fermentation et isolement de cyclosporine A ainsi que de nouvelles souches productrices de cyclosporine
ZA923641B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
US5578444A (en) 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
GB9116470D0 (en) 1991-07-30 1991-09-11 Erba Carlo Spa 2-(imidazol-1-yl)-benzylethylidene-aminoxyalkanoic acid derivatives
WO1993003729A1 (fr) 1991-08-12 1993-03-04 Research Corporation Technologies, Inc. Phenoxazines n-substituees utilisees dans le traitement de cellules cancereuses resistant a de multiples medicaments
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
US5972630A (en) * 1991-08-19 1999-10-26 Dade Behring Marburg Gmbh Homogeneous immunoassays using enzyme inhibitors
US5217586A (en) 1992-01-09 1993-06-08 International Business Machines Corporation Electrochemical tool for uniform metal removal during electropolishing
US5190972A (en) 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
GB9206648D0 (en) 1992-03-26 1992-05-06 Leo Pharm Prod Ltd Chemical compounds
US5637317A (en) 1992-05-18 1997-06-10 Dietl; Hans Pharmaceutical preparation containing cyclosporin(s) for oral administration and process for producing same
EP0570829B1 (fr) 1992-05-18 2001-04-25 CicloMulsion AG Composition pharmacéutique pour administration intraveneuse contenant de la cyclosporine et méthode pour sa préparation
HU213553B (en) 1992-05-25 1997-07-28 Biogal Gyogyszergyar Process for isolating of cyclosporin-a
AU4400593A (en) 1992-06-05 1994-01-04 Abbott Laboratories Methods and reagents for the determination of immunosuppressive agents
CA2138542A1 (fr) 1992-06-23 1994-01-06 Masaaki Ishizuka Nouveaux antibiotiques possedant une action immuno-suppressive, delamynomycines et leur mode de production
GB9214202D0 (en) 1992-07-03 1992-08-12 Leo Pharm Prod Ltd Chemical compounds
EP0578616A3 (en) 1992-07-09 1994-06-01 Sandoz Ltd Cylosporin synthetase
CZ278863B6 (en) 1992-09-07 1994-07-13 Galena Medicinal preparations with n-methylated cyclic undecapeptides
GB9220439D0 (en) 1992-09-28 1992-11-11 Leo Pharm Prod Ltd Chemical compounds
US5318895A (en) 1992-10-05 1994-06-07 Merck & Co., Inc. Aspergillus niger mutants
US5589458A (en) 1992-11-13 1996-12-31 Thomas Jefferson University Compounds that inhibit T cell proliferation and methods for using the same
US5298523A (en) 1992-12-14 1994-03-29 Harbor Branch Oceanographic Institution, Inc. Method for treating transplant patients using mycalamide compounds
GB9226877D0 (en) 1992-12-23 1993-02-17 Leo Pharm Prod Ltd Chemical compounds
CA2086267A1 (fr) 1992-12-24 1994-06-25 Argyrios Margaritis Derives et conjugues derives de la cyclosporine
FI92334C (fi) 1992-12-30 1994-10-25 Leiras Oy Menetelmä syklosporiinien tuottamiseksi ja menetelmässä käytettävä uusi Tolypocladium-kanta
US5393669A (en) 1993-02-05 1995-02-28 Martek Biosciences Corp. Compositions and methods for protein structural determinations
US5834266A (en) 1993-02-12 1998-11-10 President & Fellows Of Harvard College Regulated apoptosis
CA2155728C (fr) * 1993-02-12 2000-04-25 Gerald R. Crabtree Transcription regulee de genes cibles et d'autres evenements biologiques
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
PT693924E (pt) 1993-02-22 2004-09-30 American Biosciences Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos
US5665383A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of immunostimulating agents for in vivo delivery
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US5468772A (en) 1993-03-10 1995-11-21 Pharmagenesis, Inc. Tripterinin compound and method
DK0697881T3 (da) 1993-04-20 2002-10-07 Novartis Ag Nye farmaceutiske præparater til oral indgivelse indeholdende cyclosporin
JPH08509368A (ja) 1993-04-23 1996-10-08 サンド・リミテッド 組換えアラニンラセマーゼおよびトリポクラジウム・ニベウムからのｇａｐｄｈ
WO1994025045A1 (fr) * 1993-05-04 1994-11-10 Merck & Co., Inc. Ethers d'aminoalkyle de cyclohexapeptidyle
DE4338086A1 (de) 1993-11-08 1995-05-11 Dietl Hans Cyclosporin(e) enthaltende pharmazeutische Zubereitung zur oralen Applikation sowie Verfahren zu ihrer Herstellung
AU7276594A (en) 1993-08-13 1995-03-14 Banyu Pharmaceutical Co., Ltd. Endothelin-antagonistic cyclopentane derivative
JP2847969B2 (ja) 1993-08-18 1999-01-20 萬有製薬株式会社 エンドセリン拮抗活性を有する複素芳香環縮合シクロペンテン誘導体
US5421987A (en) 1993-08-30 1995-06-06 Tzanavaras; George Precision high rate electroplating cell and method
US5510239A (en) 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
JP3644543B2 (ja) 1993-10-22 2005-04-27 ヘクサル・アーゲー シクロスポリンＡ及びα−トコフェロールを含有する医薬組成物
JP3696884B2 (ja) 1994-03-25 2005-09-21 アイソテクニカ、インコーポレーテッド ジュウテリウム化による薬物の効能の増強
JPH07278187A (ja) 1994-04-07 1995-10-24 Nippon Shinyaku Co Ltd シクロスポリン類のリン酸エステル誘導体及び医薬組成物
US5798386A (en) 1994-08-03 1998-08-25 Cell Therapeutics, Inc. Angiogenic lipid formulations
US5639852A (en) * 1994-09-01 1997-06-17 Wisconsin Alumni Research Foundation Immunostimulatory agents
US5948693A (en) 1994-09-01 1999-09-07 Wisconsin Alumni Research Foundation Solid phase synthesis of immunosuppressive agents
US5567300A (en) 1994-09-02 1996-10-22 Ibm Corporation Electrochemical metal removal technique for planarization of surfaces
US5554725A (en) 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
DE4433101A1 (de) 1994-09-16 1996-03-21 Bauer Kurt Heinz Prof Dr Wasserlösliche Dextranfettsäureester und ihre Verwendung als Solubilisatoren
HU215966B (hu) 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
US5648376A (en) * 1995-01-19 1997-07-15 Pharmagenesis, Inc. Immunosuppressant diterpene compound
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
IE75744B1 (en) 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
US5668734A (en) 1995-04-10 1997-09-16 The Uab Research Foundation Method for analyzing 2D transferred noesy spectra of molecules undergoing multistate conformational exchange
JPH11504028A (ja) 1995-04-24 1999-04-06 イースム リサーチ ディベロップメント カンパニー オブ ザ ヒーブル ユニバーシティ オブ エルサレム 油／水エマルジョンを作り出す自己乳化性配合物
JP3934705B2 (ja) 1995-05-26 2007-06-20 ノバルティス ファーマ株式会社 サイクロデキストリン組成物
US5624902A (en) * 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
US5616595A (en) 1995-06-07 1997-04-01 Abbott Laboratories Process for recovering water insoluble compounds from a fermentation broth
DE19521974A1 (de) 1995-06-16 1996-12-19 Hexal Pharmaforschung Gmbh Pharmazeutische Zubereitung mit Cyclosporin A
US5948884A (en) 1995-07-17 1999-09-07 C-Chem Ag Cyclosporin derivatives with anti-HIV effect
JPH0978187A (ja) 1995-09-07 1997-03-25 Daido Steel Co Ltd メッキ用快削鋼
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
EP0944394A4 (fr) 1996-03-12 2003-05-14 Picower Inst Med Res Traitement de l'infection a vih par action sur le recepteur de la cyclophiline de cellules hotes
US5840305A (en) 1996-03-14 1998-11-24 The Picower Institute For Medical Research Treatment of HIV-Infection by interfering with host cell cyclophilin receptor activity
AUPN880396A0 (en) 1996-03-21 1996-04-18 Fremantle Hospital Animal model for transplantation
DE19611094C2 (de) 1996-03-21 1999-06-17 Dresden Arzneimittel Verfahren zur Reinigung von Cyclosporin A und/oder verwandten Cyclosporinen aus einem Cyclosporin-haltigen Rohextrakt unter Anwendung chromatographischer Verfahren mit Kieselgel als Adsorbens
JPH1029979A (ja) 1996-04-12 1998-02-03 Ajinomoto Co Inc 新規ピリジン誘導体
US5750510A (en) * 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
US5747330A (en) * 1996-06-05 1998-05-05 Poli Industria Chimica Antibiotic producing microbe
US5709797A (en) * 1996-06-05 1998-01-20 Poli Industria Chimica S.P.A. Method of isolating cyclosporins
EP1017366A4 (fr) 1996-09-01 2006-03-22 Pharmos Corp Coprecipites solides augmentant la biodisponibilite de substances lipophiles
GB9619894D0 (en) 1996-09-24 1996-11-06 Celltech Therapeutics Ltd Pharmaceutical products
EP0963196B1 (fr) 1996-09-27 2005-01-19 Jagotec Ag Systeme hyaluronique d'administration de medicaments
ATE252378T1 (de) 1996-12-12 2003-11-15 Dds Drug Delivery Service Ges Zubereitung in form eines wahlweise wirkstoffhaltigen matrixmaterial-hilfsstoff compounds
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757521B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
US5843520A (en) 1997-01-13 1998-12-01 Vanguard International Semiconductor Corporation Substrate clamp design for minimizing substrate to clamp sticking during thermal processing of thermally flowable layers
JPH10251137A (ja) 1997-03-14 1998-09-22 Advanced Sukin Res Kenkyusho:Kk 光線過敏症抑制剤
FR2762843B1 (fr) 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
US5939406A (en) * 1997-07-21 1999-08-17 Wisconsin Alumni Research Foundation 18-substituted-19-nor-vitamin D compounds
WO1999010373A1 (fr) 1997-08-26 1999-03-04 Wisconsin Alumni Research Foundation Cyclosporines non immunosuppressives et utilisation de ces cyclosporines pour prevenir et traiter une infection par le vih
DE69840586D1 (de) 1997-10-08 2009-04-02 Isotechnika Inc Deuterierte Cyclosporin-analoga und ihre Verwendung als immunmodulierende Agenzien
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
FR2772768B1 (fr) * 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
US6706691B1 (en) 1998-07-15 2004-03-16 Board Of Regents, The University Of Texas System Immunosupportive drug sparing diet
US6183611B1 (en) 1998-07-17 2001-02-06 Cutek Research, Inc. Method and apparatus for the disposal of processing fluid used to deposit and/or remove material on a substrate
US6187152B1 (en) 1998-07-17 2001-02-13 Cutek Research, Inc. Multiple station processing chamber and method for depositing and/or removing material on a substrate
FI110094B (fi) 1999-09-10 2002-11-29 Ecospec Ltd Oy Menetelmä maanparannusaineen valmistamiseksi
KR100801588B1 (ko) 1999-09-21 2008-02-05 스키에파마 캐나다 인코포레이티드 생물학적 유효 물질의 표면 변형된 미립자 조성물
EP1408930A1 (fr) 1999-10-20 2004-04-21 Vesifact Ag Microemulsions preconcentrees contenant des cyclosporines et microemulsions correspondantes
WO2003004469A1 (fr) 2001-07-02 2003-01-16 Dabur Research Foundation Action anticancereuse de conjugues iminoacides de methylglyoxal
PL210697B1 (pl) 2001-10-19 2012-02-29 Isotechnika Inc Kompozycja zawierająca mieszaninę izomerów analogu cyklosporyny i zastosowanie tej mieszaniny
BRPI0213658A8 (pt) 2001-10-19 2016-12-06 F Hoffmann La Roche Ltd Método para preparar uma mistura isomérica predeterminada ou não dos análogos de ciclosporina a modificados no resíduo de 1-aminoácido, métodopara produzir uma mistura enriquecida com e-isômero ou com z-isômero de análogos de ciclosporina a modificados no resíduo de 1-aminoácido, mistura de (e) e (z)-isômeros, composição, método para a síntese estereoseletiva do z-isômero de isatx247, método para a preparação de aldeído do ciclosporina a
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
AU2004222306A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins

Also Published As

Publication number Publication date
IL160763A0 (en) 2004-08-31
MXPA04003625A (es) 2004-12-02
ZA200402269B (en) 2005-05-25
US7141648B2 (en) 2006-11-28
ES2266564T3 (es) 2007-03-01
HRP20070058B1 (hr) 2014-05-23
PT1714977E (pt) 2009-06-23
PT1436321E (pt) 2006-10-31
US20130078280A1 (en) 2013-03-28
NO332459B1 (no) 2012-09-24
PL210841B1 (pl) 2012-03-30
HRP20070058A2 (en) 2008-09-30
DE60231570D1 (de) 2009-04-23
US20170362277A1 (en) 2017-12-21
JP4261355B2 (ja) 2009-04-30
EP1714977A3 (fr) 2007-01-10
CN100334106C (zh) 2007-08-29
US20100062976A1 (en) 2010-03-11
NZ531944A (en) 2006-03-31
JP4887469B2 (ja) 2012-02-29
WO2003033526A2 (fr) 2003-04-24
PL392749A1 (pl) 2011-01-03
HRP20040355B1 (hr) 2012-10-31
ES2326040T3 (es) 2009-09-29
EP1714977A2 (fr) 2006-10-25
CA2461740C (fr) 2013-02-12
ATE425178T1 (de) 2009-03-15
AU2002331509B2 (en) 2007-12-06
HK1062568A1 (en) 2004-11-12
USRE48226E1 (en) 2020-09-29
NO20042031L (no) 2004-05-19
WO2003033526A3 (fr) 2004-02-12
EP1714977B1 (fr) 2009-03-11
EP1436321B9 (fr) 2008-11-12
HRP20040355A2 (en) 2005-04-30
US20100311944A1 (en) 2010-12-09
US20140142277A1 (en) 2014-05-22
US6998385B2 (en) 2006-02-14
DE60213115D1 (en) 2006-08-24
RU2321593C2 (ru) 2008-04-10
JP2009046515A (ja) 2009-03-05
AU2010206069A1 (en) 2010-08-19
RU2321593C9 (ru) 2008-06-20
US20050192214A1 (en) 2005-09-01
EP1436321A2 (fr) 2004-07-14
US20030212249A1 (en) 2003-11-13
PL210795B1 (pl) 2012-03-30
IL186140A (en) 2012-02-29
IL160763A (en) 2009-11-18
US20080171850A1 (en) 2008-07-17
US20140370082A1 (en) 2014-12-18
CA2461740A1 (fr) 2003-04-24
US9765119B2 (en) 2017-09-19
KR20090130195A (ko) 2009-12-18
JP2005516893A (ja) 2005-06-09
DK1436321T3 (da) 2006-11-13
US7332472B2 (en) 2008-02-19
EP1436321B1 (fr) 2006-07-12
DE60213115T2 (de) 2007-02-01
KR20050037417A (ko) 2005-04-21
CO5580836A2 (es) 2005-11-30
US20070087963A1 (en) 2007-04-19
TNSN04068A1 (en) 2006-06-01
PL370772A1 (en) 2005-05-30
IL186140A0 (en) 2008-01-20
KR101006206B1 (ko) 2011-01-07
JP5396571B2 (ja) 2014-01-22
RU2004110940A (ru) 2005-06-27
US10472394B2 (en) 2019-11-12
ATE332917T1 (de) 2006-08-15
JP2010280710A (ja) 2010-12-16
CY1105111T1 (el) 2010-03-03
BR0213658A (pt) 2004-10-26
BRPI0213658A8 (pt) 2016-12-06
KR100982466B1 (ko) 2010-09-16
CN1571795A (zh) 2005-01-26
DK1714977T3 (da) 2009-07-06
US20030139326A1 (en) 2003-07-24
SI1436321T1 (sl) 2006-12-31
US20160075741A1 (en) 2016-03-17

Similar Documents

Publication Publication Date Title
MA27293A1 (fr) Synthese d&#39;analogues de la cyclosporine
CA2312545A1 (fr) Composition pharmaceutique solide thermoformable a liberation controlee
ME00487B (fr) Melanges d&#39;analogues de cyclosporine et leur utilisation comme agents immunomodulateurs
TNSN06075A1 (fr) Phenyl-ou pyridylamides servant d&#39;antagonistes de la prostaglandine e2
HUP0101241A2 (hu) Vasalapú katalizátor alfa, omega-dinitrilek hidrogénezésére
BR9913221A (pt) Composições catalisadoras sustentadas altamente ativas
MA27154A1 (fr) Derives de quinazoline pour le traitement d&#39;une croissance cellulaire anormale
CA2565297A1 (fr) Emulsion aqueuse bitumineuse
MA28015A1 (fr) Composes chimiques
DE69327971D1 (de) Parfümierte waschmittelpulvern
TNSN04241A1 (fr) Composition herbicide
FR3115201B1 (fr) COMPOSITIONS COSMETIQUES, LEURS NECESSAIRES, ET PROCEDES DE FABRICATION et D’UTILISATION DE CELLES-CI
EP0801049A3 (fr) Dérivés de cyclopentanebutanol comme matières odorantes
CA2388347A1 (fr) Nouvelles compositions pesticides et/ou regulatrices de croissance a agent tensio-actif non ionique particulier
YU33204A (sh) Sinteza analoga ciklosporina
CA2350671A1 (fr) Association riluzole et alpha-tocopherol
YU33004A (sh) Smeša analoga ciklosporina i njihova upotreba u svojstvu imunomodulatornih supstanci
BE1002811A4 (fr) Composition herbicide et son procede de preparation.
FR3127404B1 (fr) Composition cosmétique diluée à longue tenue comprenant des modificateurs sensoriels mixtes
FR2636810A1 (fr) Procede pour maitriser des micro-organismes nuisibles utilisant des compositions a base de phosphore
RU98101442A (ru) Сплав для раскисления, легирования и модифицирования стали
TNSN86082A1 (fr) Une composition photopolymerisable et un systeme de photo- initiateur